What’s next for clinical trials? Exploring the rise of personalized research
From AI readiness to federated data networks, Mukhtar Ahmed discusses the trends shaping evidence generation and the rise of personalized research.
Building a reusable evidence foundation for confident decision-making
Building evidence that supports better decisions
Every decision that shapes a new drug’s path to market depends on evidence leaders can trust and act on. From development planning and regulatory engagement to commercialization and post-launch performance, teams need evidence that is timely, defensible, and built to support the next decision as well as the one in front of them.
As evidence needs expand and must support increasingly granular and complex questions, the opportunity is to move beyond one-off data sourcing toward a more connected foundation for decision-making. Teams need to identify the right populations, design studies around the right patients, endpoints, sites, and geographies, and generate evidence that regulators, health technology assessment (HTA) bodies, payers, clinicians, and commercial leaders can trust. After launch, that same foundation should continue to support monitoring of performance, access, outcomes, and unmet need without requiring teams to start over.
Answering those questions requires more than access to more real-world data (RWD). It requires evidence readiness: the ability to connect the right data, harmonize it consistently, govern it appropriately, and turn it into decision-ready insight across development, access, medical, and commercial teams. When data, studies, and workflows are designed to work together, organizations can reduce duplication, accelerate evidence generation, and strengthen confidence in decisions across the drug lifecycle.
More data alone does not create better decisions. RWD creates value when teams can turn it into evidence they can trust, apply, and carry forward from development through post-launch performance.
What modern evidence generation requires
A reusable evidence foundation is more than a dataset, tool, or study. It gives teams an integrated way to start with a specific evidence need, bring together the right data sources, partners, sites, geographies, and modalities, and turn those inputs into governed, analysis-ready assets that can strengthen the next decision.
As AI becomes more embedded in evidence generation, the quality, provenance, and governance of the underlying data matter even more. Models can only support better decisions when they are trained, tested, and applied on data that is research-ready, representative, and appropriately controlled.
| Capability | Why it matters |
|---|---|
| Fit-for-purpose evidence design | Starts with the scientific, clinical, regulatory, payer, or commercial decision the evidence must support. |
| Purpose-built data networks | Connects the right data sources, partners, sites, geographies, and modalities around the question at hand. |
| Harmonization and research readiness | Transforms fragmented inputs into comparable, analysis-ready data with consistent definitions and traceability. |
| Governed access and secure analytics | Supports compliant collaboration, federated or hybrid analysis, and controlled use of sensitive data. |
| Responsible AI readiness | Preserves data provenance, harmonization logic, governance controls, and auditability so AI-enabled workflows can be applied with greater confidence and oversight. |
| Reusable evidence assets | Carries forward data assets, methods, governance patterns, and workflows so teams do not have to start from scratch with each new question. |
From one-off studies to evidence that can be reused
The value of a stronger evidence foundation becomes clearest across the drug lifecycle. With the right structure in place, teams can move from understanding unmet need and defining target populations to improving trial feasibility, supporting regulatory and payer engagement, enabling medical affairs, demonstrating value after launch, and monitoring in-market performance.
Instead of rebuilding data, definitions, governance processes, and analytics workflows for every new question, organizations can carry forward the assets that make evidence generation faster and more defensible. That continuity matters most when programs are global, multi-modal, and cross-functional, where data cannot always move freely, local requirements differ, and stakeholders need comparable outputs they can trust.
For example, a team planning evidence for a new therapy may begin with feasibility and patient population insights. From there, the same governed data foundation can support regulatory engagement, payer evidence planning, medical affairs, and post-launch performance monitoring. The value comes from building data assets that can be adapted and carried forward, rather than rebuilt for each new question.
Federated and hybrid analytics models are becoming essential as more data remains under local control because of privacy, consent, residency, and institutional requirements. A reusable evidence foundation should make it possible to analyze distributed data securely while still producing comparable, decision-ready outputs across markets and partners.
Questions every evidence model should be able to answer
A practical way to assess evidence readiness is to look at whether the current model can support the decisions teams need to make now while adapting as evidence demands become more precise and sophisticated. Teams need to ask themselves:
- Can data be assembled around the evidence question rather than forcing the question to fit an existing asset?
- Can data be harmonized, documented, and governed consistently across sites, regions, and modalities?
- Can analytics run securely in centralized, federated, or hybrid models depending on privacy, consent, and data-holder requirements?
- Can outputs withstand scrutiny from internal stakeholders, regulators, payers, and external partners?
- Can the evidence foundation support responsible AI use by preserving data provenance, harmonization logic, governance controls, and auditability?
- Can evidence assets be carried forward across development, HTA, market access, medical, commercial, and post-launch decisions?
Move from fragmented data access to decision-ready evidence
Evidence generation today depends on more than access to RWD. Teams need evidence foundations that can support the decisions shaping development strategy, regulatory, HTA and payer engagement, commercialization, and post-launch performance.
As expectations rise and technologies such as AI change how evidence is generated, analyzed, and applied, teams need models that can keep pace with more precise, complex, and sophisticated evidence demands.
That means moving beyond one-off data sourcing toward an operating model where data, governance, analytics, and workflows work together to turn fragmented inputs into trusted, reusable evidence – evidence that can support the decision at hand and strengthen the ones that follow.
More from Narasimha Kumar
In “How data from medical practice can inform care,” published in MedNous, Kumar explores how real‑world data challenges traditional views of standard of care and enables more accurate, data‑driven decisions across trial design and evidence generation.
In “AI Readiness in Pharma – Getting the Foundation Right,” published in Bio‑IT World, Kumar examines how data fragmentation, complex regulations, and limited interoperability are slowing AI adoption—and what it takes to build trusted, cross‑border evidence ecosystems.
In “AI in drug development is not a data problem – it’s an evidence problem”, published in MedCity News, Kumar explores how the challenge for organizations is no longer collecting data, but preserving the context, meaning, and relationships that transform data into usable evidence.